Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2471/BLT.14.145920 http://scihub22266oqcxt.onion/10.2471/BLT.14.145920 C4431560!4431560!26229192     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Bull+World+Health+Organ 2015 ; 93 (4): 279-82 Nephropedia Template TP {{tp|p=26229192|t=2015. Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility |pdf=|usr=}}{{26229192}} gab.com Text Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility JO: Bull World Health Organ http://www.kidney.de/pget.php?&tw=1&pmid=26229192 #FOAvip Problem: Many countries have limited experience of securing the best prices for drugs and have little negotiating power. This is particularly true for the complex, lengthy and expensive regimens used to treat multidrug-resistant tuberculosis. Approach: The Stop TB Partnership?s Global Drug Facility is dedicated to improving worldwide access to antituberculosis medicines and diagnostic techniques that meet international quality standards. Local setting: The Global Drug Facility is able to secure price reductions through competitive tendering among prequalified drug manufacturers and by consolidating orders to achieve large purchase volumes. Consolidating the market in this way increases the incentives for suppliers of quality-assured medicines. Relevant changes: In 2013 the Global Drug Facility reduced the price of the second-line drugs it supplies for multidrug-resistant tuberculosis: the overall cost of the longest and most expensive treatment regimen for a patient decreased by 26% ? from 7890 United States dollars (US$) in 2011 to US$ 5822 in 2013. Lessons learnt: The price of treatment for multidrug-resistant tuberculosis supplied by the Global Drug Facility was reduced by consolidating orders to achieve large purchase volumes, by international, competitive bidding and by the existence of donor-funded medicine stockpiles. The rise in the number of suppliers of internationally quality-assured drugs was also important. The savings achieved from lower drug costs could be used to increase the number of patients on high-quality treatment. Twit Text FOAVip Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility ????Bull World Health Organ http://www.kidney.de/pget.php?&tw=1&pmid=26229192 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26229192 #FOAvip English Wikipedia <ref>{{Cite pmid|26229192}}</ref> Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility #MMPMID26229192 Lunte K; Cordier-Lassalle T; Keravec J Bull World Health Organ 2015[Apr]; 93 (4): 279-82 PMID26229192show ga Problem: Many countries have limited experience of securing the best prices for drugs and have little negotiating power. This is particularly true for the complex, lengthy and expensive regimens used to treat multidrug-resistant tuberculosis. Approach: The Stop TB Partnership?s Global Drug Facility is dedicated to improving worldwide access to antituberculosis medicines and diagnostic techniques that meet international quality standards. Local setting: The Global Drug Facility is able to secure price reductions through competitive tendering among prequalified drug manufacturers and by consolidating orders to achieve large purchase volumes. Consolidating the market in this way increases the incentives for suppliers of quality-assured medicines. Relevant changes: In 2013 the Global Drug Facility reduced the price of the second-line drugs it supplies for multidrug-resistant tuberculosis: the overall cost of the longest and most expensive treatment regimen for a patient decreased by 26% ? from 7890 United States dollars (US$) in 2011 to US$ 5822 in 2013. Lessons learnt: The price of treatment for multidrug-resistant tuberculosis supplied by the Global Drug Facility was reduced by consolidating orders to achieve large purchase volumes, by international, competitive bidding and by the existence of donor-funded medicine stockpiles. The rise in the number of suppliers of internationally quality-assured drugs was also important. The savings achieved from lower drug costs could be used to increase the number of patients on high-quality treatment. äReducing the price of treatment for multidrug-resistant tuberculosis t(epmc).pdf DeepDyve Pubget Overpricing